A01K 2207/12
Animals modified by administration of exogenous cells
A01K2207/12 (Animals modified by administration of exogenous cells) appears on 362 US grants and 806 published applications in this corpus.
Search patents in A01K- Granted patents
- 362
- Published applications
- 806
- Assignees
- 449
- Inventors
- 1,743
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 2 |
| 2006 | 0 | 1 |
| 2007 | 1 | 0 |
| 2008 | 0 | 5 |
| 2009 | 2 | 2 |
| 2010 | 2 | 4 |
| 2011 | 1 | 12 |
| 2012 | 3 | 13 |
| 2013 | 5 | 25 |
| 2014 | 8 | 17 |
| 2015 | 11 | 38 |
| 2016 | 16 | 53 |
| 2017 | 24 | 42 |
| 2018 | 20 | 45 |
| 2019 | 21 | 59 |
| 2020 | 25 | 76 |
| 2021 | 34 | 95 |
| 2022 | 27 | 85 |
| 2023 | 39 | 61 |
| 2024 | 41 | 81 |
| 2025 | 42 | 53 |
| 2026 | 37 | 37 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Genetically modified non-human animal with human or chimeric TFR122 Sep 2026US 12,740,550 B2Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Oligodendrocyte progenitor cell compositions25 Aug 2026US 12,716,054 B2Asterias Biotherapeutics, Inc.
- Genetically modified non-human animals expressing human EPO4 Aug 2026US 12,696,884 B2Institute for Research in Biomedicine (IRB)
- Formation of three-dimensional organ from pluripotent stem cells4 Aug 2026US 12,698,480 B2Public University Corporation Yokohama City University
- Modulating TLR/NF-KB and P53 signaling pathways to enhance interspecies chimerism between evolutionaryily distant species14 Jul 2026US 12,680,084 B2Board of Regents, The University of Texas System
- Genetically Modified Non-Human Animals and Methods of Use Thereof8 Oct 2026US 2026/0305588 A1Institute for Research in Biomedicine (IRB)
- Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse8 Oct 2026US 2026/0308532 A1Fred Hutchinson Cancer Center
- Nf2-associated meningioma model24 Sep 2026US 2026/0286314 A1
- Antibody against hepatitis b virus, preparation thereof and use thereof27 Aug 2026US 2026/0250361 A1Huahui Health Ltd.
- Quadricistronic system comprising a homing receptor and chimeric antigen receptor for stable genetic modification of cellular immunotherapies20 Aug 2026US 2026/0242801 A1ImmunityBio, Inc.
Most cited
By later US patents
- Method for generating an animal homozygous for a genetic modification199US 7,294,754 B2Regeneron Pharmaceuticals, Inc. · 2007
- Method for making homozygous genetic modifications111US 7,659,442 B2Regeneron Pharmaceuticals, Inc. · 2010
- Method for making genetic modifications97US 7,576,259 B2Regeneron Pharmaceuticals, Inc. · 2009
- Human SIRPAalpha transgenic animals and their methods of use34US 9,402,377 B2Yale University · 2016
- Non-human animals having a humanized signal-regulatory protein gene29US 9,127,292 B2Regeneron Pharmaceuticals, Inc. · 2015